**Vitamin A (Rifafour) (TB-1002)**

Full Title: Randomized controlled trial to assess the efficacy of vitamin A and zinc supplementation on sputum smear and culture conversion and time to culture detection in adults with sputum smear-positive pulmonary tuberculosis, at the Delft Community Health Centre in Cape Town, South Africa.

Treatment: Vitamin A/HRZE and HRZE

ClinicalTrials.gov Identifier: N/A

**PA-824 (50-200mg) (TB-1003)**

Full Title: “A Phase II Dose Ranging Trial to Evaluate the Extended Early Bactericidal Activity, Safety, Tolerability, and Pharmacokinetics of PA-824 in Adult Participants with Newly Diagnosed, Uncomplicated, Smear-Positive, Pulmonary Tuberculosis.”

Treatment: Pa and HRZE

ClinicalTrials.gov Identifier: NCT00944021

<https://clinicaltrials.gov/ct2/show/NCT00944021?term=CL-010&rank=1>

**TMC207-TiDP13-C208 (TB-1004)**

Full Title: “TMC207-TiDP13-C208: Anti-bacterial Activity, Safety, and Tolerability of TMC207 in Participants With Multi-drug Resistant Mycobacterium Tuberculosis (MDR-TB)”

Treatment: B/HRZE and HRZE

ClinicalTrials.gov Identifier: NCT00449644

<https://clinicaltrials.gov/ct2/show/NCT00449644?term=TMC207-TiDP13-C208&rank=1>

**TMC207 CL-001 (TB-1005)**

Full Title: Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis

Treatment: B and HRZE

ClinicalTrials.gov Identifier: NCT01215110

<https://clinicaltrials.gov/ct2/show/NCT01215110?term=TMC207+CL-001&rank=1>

**PA-824 (200-1200mg) (TB-1007)**

Full Title:” A Phase IIa Trial to Evaluate the Safety, Tolerability, Extended Early Bactericidal Activity and Pharmacokinetics of 14 Days' Treatment With Four Oral Doses of PA-824 in Adult Participants With Newly Diagnosed, Uncomplicated, Smear-Positive, Pulmonary Tuberculosis”

Treatment: Pa and HRZE

ClinicalTrials.gov Identifier: NCT00567840

<https://clinicaltrials.gov/ct2/show/NCT00567840?term=CL-007&rank=1>

**J-M-Pa-Z (TB-1008)**

Full Title: Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With(J-M-Pa-Z) (NC-001)

Treatment: B, B/PA, B/Z, HRZE, Pa/Z, and Pa/Z/M

ClinicalTrials.gov Identifier: NCT01215851

<https://clinicaltrials.gov/ct2/show/NCT01215851?term=J-M-Pa-Z&rank=1>

**TBTC 28 (TB-1009)**

Full Title: “TBTC Study 28: Moxifloxacin Versus Isoniazid for TB Treatment”

Treatment: HRZE and MRZE

ClinicalTrials.gov Identifier: NCT00144417

<https://clinicaltrials.gov/ct2/show/NCT00144417?term=TBTC+28&rank=2>

**TBTC 29 (TB-1010)**

Full Title: “TBTC Study 29: Rifapentine During Intensive Phase Tuberculosis (TB) Treatment”

Treatment: PHZE and HRZE

ClinicalTrials.gov Identifier: NCT00694629

<https://clinicaltrials.gov/ct2/show/NCT00694629?term=TBTC+29&rank=3>

**PA-824 NC-002-(M-Pa-Z) (TB-1011)**

Full Title: “Evaluation of 8 Weeks of Treatment With the Combination of Moxifloxacin, PA-824 and Pyrazinamide in Patients With Drug Sensitive and Multi Drug-Resistant Pulmonary Tuberculosis (TB) (NC-002)”

Treatment: Pa/Z/M and HRZE

ClinicalTrials.gov Identifier: NCT01498419

<https://clinicaltrials.gov/ct2/show/NCT01498419?term=PA-824+NC-002-%28M-Pa-Z%29&rank=1>

**TBTC 29X (TB-1013)**

Full Title: “TBTC Study 29X: Enrollment complete in the main study (TBTC 29). Study amended with extension to evaluate safety of higher rifapentine doses.”

Treatment: PHZE and HRZE

ClinicalTrials.gov Identifier: NCT00694629

<https://clinicaltrials.gov/ct2/show/NCT00694629?term=TBTC+Study+29&rank=1>

**PA-824 NC-003-(C-J-Pa-Z) (TB-1014)**

Full Title: “Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With Clofazimine (C)-TMC207 (J)-PA-824 (Pa)-Pyrazinamide (Z) (NC-003)”

Treatment: B/Pa/Z/Cfz, B/Pa/Cfz, B/Pa/Z, B/Z/Cfz, Cfz, HRZE, and Z.

ClinicalTrials.gov Identifier: NCT01691534

<https://clinicaltrials.gov/ct2/show/NCT01691534?term=PA-824+NC-003-%28C-J-Pa-Z%29&rank=1>